These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32914036)

  • 41. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.
    Cavanna L; Stroppa EM; Citterio C; Mordenti P; Di Nunzio C; Peveri S; Orlandi E; Vecchia S
    Onco Targets Ther; 2019; 12():3077-3085. PubMed ID: 31118666
    [No Abstract]   [Full Text] [Related]  

  • 42. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
    Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.
    Mehta VK; Fisher G; Ford JA; Poen JC; Vierra MA; Oberhelman H; Niederhuber J; Bastidas JA
    J Gastrointest Surg; 2001; 5(1):27-35. PubMed ID: 11309645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma.
    Wu MY; Shen M; Xu MD; Yu ZY; Tao M
    Gland Surg; 2020 Dec; 9(6):2125-2135. PubMed ID: 33447563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection.
    Zaid M; Elganainy D; Dogra P; Dai A; Widmann L; Fernandes P; Wang Z; Pelaez MJ; Ramirez JR; Singhi AD; Dasyam AK; Brand RE; Park WG; Rahmanuddin S; Rosenthal MH; Wolpin BM; Khalaf N; Goel A; Von Hoff DD; Tamm EP; Maitra A; Cristini V; Koay EJ
    Front Oncol; 2020; 10():596931. PubMed ID: 33344245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma.
    González-Borja I; Viúdez A; Alors-Pérez E; Goñi S; Amat I; Ghanem I; Pazo-Cid R; Feliu J; Alonso L; López C; Arrazubi V; Gallego J; Pérez-Sanz J; Hernández-García I; Vera R; Castaño JP; Fernández-Irigoyen J
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Sanford DE; Porembka MR; Panni RZ; Mitchem JB; Belt BA; Plambeck-Suess SM; Lin G; Denardo DG; Fields RC; Hawkins WG; Strasberg SM; Lockhart AC; Wang-Gillam A; Goedegebuure SP; Linehan DC
    J Cancer Ther; 2013 May; 4(3):797-803. PubMed ID: 24089656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial.
    Testoni SGG; Petrone MC; Reni M; Rossi G; Barbera M; Nicoletti V; Gusmini S; Balzano G; Linzenbold W; Enderle M; Della-Torre E; De Cobelli F; Doglioni C; Falconi M; Capurso G; Arcidiacono PG
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural History of Stage IV Pancreatic Cancer. Identifying Survival Benchmarks for Curative-intent Resection in Patients With Synchronous Liver-only Metastases.
    Kaslow SR; Sacks GD; Berman RS; Lee AY; Correa-Gallego C
    Ann Surg; 2023 Oct; 278(4):e798-e804. PubMed ID: 36353987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study.
    Zaid M; Widmann L; Dai A; Sun K; Zhang J; Zhao J; Hurd MW; Varadhachary GR; Wolff RA; Maitra A; Katz MHG; Herman JM; Wang H; Knopp MV; Williams TM; Bhosale P; Tamm EP; Koay EJ
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual-energy computed tomography-based iodine concentration as a predictor of histopathological response to preoperative chemoradiotherapy for pancreatic cancer.
    Ohira S; Ikawa T; Kanayama N; Minamitani M; Kihara S; Inui S; Ueda Y; Miyazaki M; Yamashita H; Nishio T; Koizumi M; Nakagawa K; Konishi K
    J Radiat Res; 2023 Nov; 64(6):940-947. PubMed ID: 37839063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma.
    Jain AJ; Maxwell JE; Katz MHG; Snyder RA
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627202
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.